BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37879679)

  • 41. HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis.
    La Torre G; de Waure C; Chiaradia G; Mannocci A; Ricciardi W
    Vaccine; 2007 Dec; 25(50):8352-8. PubMed ID: 17996990
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human Papillomavirus Genotyping Compared With a Qualitative High-Risk Human Papillomavirus Test After Treatment of High-Grade Cervical Intraepithelial Neoplasia: A Systematic Review.
    Bottari F; Iacobone AD; Passerini R; Preti EP; Sandri MT; Cocuzza CE; Gary DS; Andrews JC
    Obstet Gynecol; 2019 Sep; 134(3):452-462. PubMed ID: 31403602
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.
    Harper DM; Franco EL; Wheeler CM; Moscicki AB; Romanowski B; Roteli-Martins CM; Jenkins D; Schuind A; Costa Clemens SA; Dubin G;
    Lancet; 2006 Apr; 367(9518):1247-55. PubMed ID: 16631880
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Updated clinical guideline for human papillomavirus vaccine: the Korean Society of Gynecologic Oncology guidelines.
    Cho HW; Min KJ; Kwon SH; Kim K; Kim S; Seong SJ; Song YJ; Lee KH; Lee SW; Lee JW; Ju W; Kim YT; Lee JK
    J Gynecol Oncol; 2021 Nov; 32(6):e94. PubMed ID: 34708596
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
    ; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R
    BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of photodynamic therapy for cervical intraepithelial neoplasia and human papilloma virus infection: A systematic review and meta-analysis of randomized clinical trials.
    Zhang W; Zhang A; Sun W; Yue Y; Li H
    Medicine (Baltimore); 2018 May; 97(21):e10864. PubMed ID: 29794788
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The impact of human papillomavirus type on colposcopy performance in women offered HPV immunisation in a catch-up vaccine programme: a two-centre observational study.
    Munro A; Gillespie C; Cotton S; Busby-Earle C; Kavanagh K; Cuschieri K; Cubie H; Robertson C; Smart L; Pollock K; Moore C; Palmer T; Cruickshank ME
    BJOG; 2017 Aug; 124(9):1394-1401. PubMed ID: 28102931
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.
    Drolet M; Bénard É; Pérez N; Brisson M;
    Lancet; 2019 Aug; 394(10197):497-509. PubMed ID: 31255301
    [TBL] [Abstract][Full Text] [Related]  

  • 49. National genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: a systematic review and meta-analysis protocol.
    Palmer M; Katanoda K; Saito E; Martellucci CA; Ostuki S; Nomura S; Ota E; Brotherton JML; Hocking J
    Syst Rev; 2021 May; 10(1):135. PubMed ID: 33952342
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: systematic reviews and economic evaluation.
    Peron M; Llewellyn A; Moe-Byrne T; Walker S; Walton M; Harden M; Palmer S; Simmonds M
    Health Technol Assess; 2018 Sep; 22(54):1-260. PubMed ID: 30284968
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
    Trimble CL; Morrow MP; Kraynyak KA; Shen X; Dallas M; Yan J; Edwards L; Parker RL; Denny L; Giffear M; Brown AS; Marcozzi-Pierce K; Shah D; Slager AM; Sylvester AJ; Khan A; Broderick KE; Juba RJ; Herring TA; Boyer J; Lee J; Sardesai NY; Weiner DB; Bagarazzi ML
    Lancet; 2015 Nov; 386(10008):2078-2088. PubMed ID: 26386540
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
    Skinner SR; Szarewski A; Romanowski B; Garland SM; Lazcano-Ponce E; Salmerón J; Del Rosario-Raymundo MR; Verheijen RH; Quek SC; da Silva DP; Kitchener H; Fong KL; Bouchard C; Money DM; Ilancheran A; Cruickshank ME; Levin MJ; Chatterjee A; Stapleton JT; Martens M; Quint W; David MP; Meric D; Hardt K; Descamps D; Geeraerts B; Struyf F; Dubin G;
    Lancet; 2014 Dec; 384(9961):2213-27. PubMed ID: 25189358
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial.
    Zhao FH; Zhu FC; Chen W; Li J; Hu YM; Hong Y; Zhang YJ; Pan QJ; Zhu JH; Zhang X; Chen Y; Tang H; Zhang H; Durand C; Datta SK; Struyf F; Bi D;
    Int J Cancer; 2014 Dec; 135(11):2604-11. PubMed ID: 24740547
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The efficacy of human papillomavirus prophylactic vaccination after conization in preventing cervical intraepithelial neoplasia recurrence: A prospective observational study in China.
    Chen M; Li C; Cui Q; Zhou C; Chen P; Yao S
    Eur J Obstet Gynecol Reprod Biol; 2023 Jul; 286():10-15. PubMed ID: 37159990
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review.
    Harder T; Wichmann O; Klug SJ; van der Sande MAB; Wiese-Posselt M
    BMC Med; 2018 Jul; 16(1):110. PubMed ID: 30016957
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Human papillomavirus vaccines and adolescents.
    Kahn JA; Bernstein DI
    Curr Opin Obstet Gynecol; 2005 Oct; 17(5):476-82. PubMed ID: 16141761
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
    Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
    Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.
    Paavonen J; Jenkins D; Bosch FX; Naud P; Salmerón J; Wheeler CM; Chow SN; Apter DL; Kitchener HC; Castellsague X; de Carvalho NS; Skinner SR; Harper DM; Hedrick JA; Jaisamrarn U; Limson GA; Dionne M; Quint W; Spiessens B; Peeters P; Struyf F; Wieting SL; Lehtinen MO; Dubin G;
    Lancet; 2007 Jun; 369(9580):2161-2170. PubMed ID: 17602732
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Description of a seven-year prospective study of human papillomavirus infection and cervical neoplasia among 10000 women in Guanacaste, Costa Rica,
    Bratti MC; Rodríguez AC; Schiffman M; Hildesheim A; Morales J; Alfaro M; Guillén D; Hutchinson M; Sherman ME; Eklund C; Schussler J; Buckland J; Morera LA; Cárdenas F; Barrantes M; Pérez E; Cox TJ; Burk RD; Herrero R
    Rev Panam Salud Publica; 2004 Feb; 15(2):75-89. PubMed ID: 15030652
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Timing of HPV vaccination as adjuvant treatment of CIN2+ recurrence in women undergoing surgical excision: a meta-analysis and meta-regression.
    Petráš M; Dvořák V; Lomozová D; Máčalík R; Neradová S; Dlouhý P; Malinová J; Rosina J; Lesná IK
    Sex Transm Infect; 2023 Dec; 99(8):561-570. PubMed ID: 37553234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.